You're reading an article by Simply Safe Dividends, the makers of online portfolio tools for dividend investors. Try our service FREE for 14 days or see more of our most popular articles

Medtronic plc (MDT)

Medtronic (MDT) is one of the classic American success stories, having been founded in 1949 by Earl Bakken and his brother-in-law, Palmer Hermundslie, in a Minnesota medical equipment repair shop.

Over the course of nearly 70 years, the company has grown into one of the world’s largest medical equipment device companies, helping to treat over 40 medical conditions and 70 million patients around the world in 2017. The company's medical supplies products are used primarily in hospitals, surgi-centers and alternate care facilities, such as home care and long-term care facilities.

Medtronic's business mix changed significantly when the company acquired Covidien for roughly $50 billion in January 2015. The deal expanded Medtronic's presence in faster-growing emerging markets, bolstered the size and scope of its portfolio of hospital supplies, and helped the company avoid some taxes by relocating its headquarters overseas. 

Acquiring Covidien about doubled Medtronic’s revenue and should help it gain more leverage and prominence on hospitals’ supplier lists as they increasingly look to cut costs.

Prior to the acquisition, Medtronic was primarily known for its cardiac and coronary devices (e.g. defibrillators, pacemakers, valves, and heart stents), diabetes care, spinal fusion, and neural stimulation businesses. Covidien focused on hospital and medical supplies, equipment for surgeries (e.g. surgical staplers), and its vascular therapies.

Today the company’s diverse portfolio of products is organized into four main business units with positions in many faster-growing medical technology markets:

  • Cardiac & Vascular (36% of revenue): pacemakers, implantable defibrillators, cardiac monitoring and diagnostic systems, and heart valves.
  • Minimally Invasive Therapy (33%): electrosurgical tools, fixation meshes, blood vessel sealing technology, vessel ablation products (for prevention of heart attacks and strokes), and patient monitoring systems such as endoscopic devices.
  • Restorative Therapies (25%): for helping patients with brain, pain, and injury recovery, as well as specialty needs such as reproductive and digestive problems.
  • Diabetes (6%): real-time blood sugar tracking and insulin management pumps, as well as less invasive diabetes treatment systems.
Source: Medtronic Investor Presentation
By geography, Medtronic generates approximately 56% of its revenue in the U.S., followed by international developed markets (31%) and emerging markets (13%), which are consistently recording double-digit growth.

Business Analysis

Medtronic’s success over the decades has largely stemmed from its unrelenting focus on continually innovating new medical products to meet needs of a fast-growing and aging global population.

That means a rich history of large R&D spending (typically around 7-8% of total revenue), which has led to over 4,600 patents for world-changing inventions such as the pacemaker in 1957.

More importantly for income investors, who have been attracted to the company’s impressive dividend growth record, Medtronic appears to enjoy a wide moat, courtesy of its quest to diversify into treating a growing range of medical conditions in its core business units, which have relatively large switching costs.

This can be seen in the company’s large development pipeline and future technology plans, which cover everything from surgical robotics systems to vessel sealing instruments.
Source: Medtronic Investor Presentation
Given the price-sensitive nature of the healthcare industry, developing successful new technologies and medical devices is essential to maintaining market share and healthy profitability.

Many of Medtronic’s medical devices also significantly impact patients’ quality of life and must be of extremely high quality. The company’s specialized products can offer superior performance in many instances, allowing Medtronic to maintain strong market share and profitability.

In addition, thanks to a disciplined and well executed acquisition strategy, such as its $50 billion acquisition of Covidien, Medtronic has been able to extend its sales reach into new promising treatment areas, as well as faster-growing emerging markets.
Source: Medtronic Investor Presentation
Just as importantly, Medtronic continues to make frequent, smaller tuck-in acquisitions to help it maintain and increase its lead in advanced medical technology.
Source: Medtronic Investor Presentation
This combination of operating in a defensive (i.e. recession resistant) industry, investing heavily in R&D, and making smart acquisitions has allowed Medtronic to generate positive sales growth for more than 10 consecutive years.

Most importantly, Medtronic’s management team has proven to be a group of skilled capital allocators. As a result, Medtronic has consistently delivered on its long-term profitability goals, such as the $850 million to $875 million in synergistic cost savings that were an important component of the decision to buy Covidien.
Source: Medtronic Investor Presentation
Combined with a willingness to part with slower-growing and less profitable businesses, such as selling its medical supplies business to Cardinal Health (CAH) for $6.1 billion in 2017, Medtronic has been able to consistently achieve impressive operating margins north of 15%.

The company's solid profitability has also helped it generate excellent free cash flow. Management has committed to return at least 50% of free cash flow to shareholders in the form of buybacks and dividends. 

Of course, a shareholder-friendly corporate culture, while necessary for a dividend aristocrat, isn’t sufficient. Management also has to strike a good balance between using cash flow to invest in the company’s future growth, maintain a strong balance sheet, and reward income investors with the steadily rising dividend they’ve come to expect from the company.

Fortunately, Medtronic has a solid capital allocation strategy that should serve it well in the future. The company expects to use its free cash flow and healthy balance sheet to continue rewarding shareholders while selectively reinvesting in opportunities that allow it to maintain a healthy investment-grade credit rating.
Source: Medtronic Investor Presentation
All of which means that Medtronic, thanks to its large economies of scale, strong dedication to R&D, new product development, and opportunities in emerging markets, should be able to deliver on its mid-single digit annual revenue goal and continue its impressive dividend growth track record for years to come.

Overall, Medtronic’s primary advantages come from its ability to continuously develop specialized medical devices in high profit and fast-growing areas of the healthcare market. The company’s diversified product portfolio and the recession-resistant nature of its products provide reliable free cash flow which can be reinvested into the business to drive future growth.

As the healthcare industry focuses more on taking out costs, larger vendors such as Medtronic should benefit because of their economies of scale, product breadth, unique technologies, and existing customer relationships.

Key Risks

Dividend aristocrats are generally low-risk stocks, given their long track records of steadily growing sales, earnings, and cash flow, long-term focused management teams, and shareholder-friendly corporate cultures. However, that doesn’t mean there aren’t risks to consider.

For example, because Medtronic’s sales are increasingly coming from overseas, the company has growing foreign exchange risk. Specifically, if the U.S. dollar is very strong, the company's reported sales and earnings growth can face headwinds. Fortunately, this risk shouldn't affect Medtronic's long-term potential.

Next, while Medtronic has a generally good history of acquisitions, both large and small, investors need to realize that every deal comes with a substantial amount of execution risk. Management could overpay for a company or fail to achieve expected synergies from a large acquisition in the future, for example. 

Risks can be even higher in the medical field where small bolt-on acquisitions, which make up the majority of Medtronic’s deal flow, are with privately held companies. 

Not only is it harder to value such firms, but because many of their products are in early development, it can take several years and millions of dollars of further R&D before Medtronic sees any sales or earnings to recoup its investment.

The biggest risk of all, however, is government regulation and potential changes to Federal healthcare policy.

For example, while the passage of the Affordable Care Act (i.e. ObamaCare) resulted in 17 million Americans gaining healthcare coverage, and thus increasing Medtronic’s customer base, the law also instituted a 2.3% medical products excise tax which lowered the company’s profits.

The tax was suspended from 2016 through 2017, but despite efforts by the Trump administration to repeal the tax, it went back into effect for 2018. Furthermore, the penalty for Americans not complying with the Obamacare individual mandate was repealed as part of the tax bill that passed in December 2017.  The Congressional Budget Office expects that the repeal will result in four million more uninsured by 2019 and 13 million more by 2027. 

Should future healthcare reform initiatives result in lower spending and more Americans losing health insurance coverage, Medtronic could face a scenario in which its slower future earnings potential (from higher medical taxes) is no longer offset by the increased demand created by more customers. The company's international diversification helps mitigate this risk to a degree, but the U.S. remains its most important region. 

Most medical device markets are fairly ruthless as well, despite some of their high-tech innovations. Products generally have short life cycles, are notoriously price-sensitive, and require constant R&D to maintain their market share.

Medtronic has meaningful scale ($30 billion in sales), strong market positions in its key segments, and a highly diversified product portfolio, but the company still had to reduce prices meaningfully during 2010-11 as the economy was slow to recover from the recession.

Closing Thoughts on Medtronic

While Medtronic’s low yield may not make it an option for all dividend investors, the company is one of the fastest-growing and perhaps most appealing dividend aristocrats in the healthcare sector.

Not only has Medtronic’s long track record of double-digit dividend growth proven its business model has staying power in all sorts of economic, political, and interest rate environments, but its future dividend growth potential remains very attractive.

Despite some of the uncertainty surrounding future government healthcare reform, it’s hard not to like the company’s diversified cash flow generated from numerous product lines, Medtronic’s large scale, which makes it an even more compelling supplier for hospitals, and the company’s exposure to emerging markets and an aging global population, which will likely drive greater demand for medical devices over the coming years.

Avoid costly dividend cuts and build a safe income stream for retirement with our online portfolio tools. Try Simply Safe Dividends FREE for 14 days

More from Intelligent Income

Idea Lists